AMPH
Amphastar Pharmaceuticals, Inc.
Key Financials
Gross Profit
$356.1M
↓ 4.8%
Revenue
$719.9M
↓ 1.7%
Net Income
$98.1M
↓ 38.5%
EPS (Diluted)
$2.03
↓ 33.7%
Operating Income
$140.4M
↓ 31.7%
Shareholders' Equity
$445.5M
↑ 10.7%
Total Assets
$1.6B
↑ 3.3%
Total Liabilities
$840.5M
↓ 0.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| ARS | 4/13/2026 | View on SEC |
| DEFA14A | 4/13/2026 | View on SEC |
| DEF 14A | 4/13/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AMPH |
| Company Name | Amphastar Pharmaceuticals, Inc. |
| CIK | 1297184 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 909-980-9484 |